Xcout Intel
Crucible Therapeutics
Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.
Subscribe to see Crucible Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Crucible Therapeutics at a glance
Crucible Therapeutics is a biotechnology company. Its most recent funding round, Seed, closed in January 2023. Xcout tracks 2 named people at Crucible Therapeutics, including Cliff Holloway (Chief Executive Officer).
Crucible Therapeutics leadership
- Cliff HollowayChief Executive Officer
- Neill Moray MackenzieExecutive Chairman of the Board and Entrepreneur-in-Residence at Argobio Studios
Crucible Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | Undisclosed | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Crucible Therapeutics competitors
A few of Crucible Therapeutics's closest competitors — see the full list of competitors and alternatives →
Harness Therapeutics Ltd. is a biotechnology company founded in 2023 and based in Cambridge, United Kingdom. The company focuses on RNA biology and the development of novel therapeutics for the treatment of neurodegenerative diseases.
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Rinri Therapeutics is a private biotechnology company headquartered in Sheffield, South Yorkshire, United Kingdom. Founded in 2018, the firm focuses on regenerative medicine research to develop first-in-class therapeutics for treating hearing loss and neurological conditions.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Get Crucible Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Crucible Therapeutics in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access